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Abstract 
Background: Body mass index (BMI) has a U‑shaped association with lung cancer risk. However, the effect of BMI on 
prognosis is controversial. This retrospective study aimed to investigate the effect of BMI on the survival of patients 
with stage I non‑small cell lung cancer (NSCLC) after surgical resection.
Methods: In total, 624 consecutive stage I NSCLC patients who underwent radical resection were classified into four 
groups according to their BMI: underweight (BMI < 18.5 kg/m2), normal weight (BMI = 18.5–22.4 kg/m2), overweight 
(BMI = 22.5–28.0 kg/m2), and obese (BMI > 28.0 kg/m2). The effect of BMI on progression‑free survival (PFS) and over‑
all survival (OS) was estimated using the Kaplan–Meier method and Cox proportional hazards model. Postoperative 
complications in each group were analyzed using the Chi square test or Fisher’s exact test.
Results: A univariate analysis showed that PFS and OS were longer in the overweight group than in other groups 
(both P < 0.05). A multivariate analysis showed that OS was longer in the overweight group than in other groups 
(compared with the other three groups in combination: hazard ratio [HR] = 1.87, 95% confidence interval [CI] 
1.30–2.68, P = 0.003; compared with the underweight group: HR = 2.24, 95% CI 1.18–4.25, P = 0.013; compared with 
the normal weight group: HR = 1.58, 95% CI 1.07–2.33, P = 0.022; compared with the obese group: HR = 2.87, 95% 
CI 1.48–5.59, P = 0.002), but PFS was similar among the groups (HR = 1.28, 95% CI 0.97–1.68, P = 0.080). A subgroup 
analysis showed an association between being overweight and prolonged OS in patients at stage T1a (P = 0.024), T1b 
(P = 0.051), and T2a (P = 0.02), as well as in patients with a non‑smoking history (P = 0.001). Overweight patients had 
lower rates of postoperative complications, such as respiratory failure (compared with the underweight and obese 
groups: P = 0.014), myocardial infarction (compared with the obese group: P = 0.033), and perioperative death (com‑
pared with the other three groups: P = 0.016).
Conclusions: Preoperative BMI is an independent prognostic factor for stage I NSCLC patients after resection, with 
overweight patients having a favorable prognosis.
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Background
The global incidence and mortality of lung cancer are the 
highest among all cancers. Furthermore, lung cancer is 
responsible for numerous public health problems [1–3]. 
Despite advances in surgical techniques and the incorpo-
ration of new therapeutic approaches, the 5-year survival 
rate for lung cancer patients has remained low [1, 4].
Strong evidence indicates that nutritional status, 
including weight and diet, might affect long-term survival 
of patients with certain types of cancer [5, 6]. The asso-
ciation between the body mass index (BMI) and the risk 
of lung cancer has been well established [7–12]. Some 
studies have shown that lung cancer mortality is lower 
in obese patients [13–16], but these studies have lacked 
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details, such as histological type, disease stage, and treat-
ment modality. Other studies, which only focused on 
advanced non-small cell lung cancer (NSCLC), showed 
that a lower BMI was related to a higher mortality [17]. 
An association between BMI and the survival of patients 
with operable early-stage NSCLC has not yet been defini-
tively demonstrated. This association could help surgeons 
identify patients at high risk of recurrence or death.
Directing the treatment and accurately predicting the 
prognosis of early-stage NSCLC patients are important, as 
is increasing public awareness of the role lifestyle plays in 
cancer survivorship. The World Health Organization has 
recommended BMI cutoff points for underweight, nor-
mal weight, overweight, and obese, which are calculated 
to predict health risks, including the risks for all types of 
cancer and non-cancer disease [18, 19]. However, whether 
these cutoff points are suitable for the Asian population 
has remained a matter of debate [20]. In two large cohort 
studies that examined the association between BMI and 
lung cancer risk in the Chinese population, Yang et  al. 
[13] used the BMI cutoff points of 18.5, 20.0, 22.4, and 
25.0  kg/m2 for underweight, normal weight, overweight, 
and obese, respectively, whereas Koh et al. [21] proposed 
the cutoff points of 20.0, 24.0, and 28.0 kg/m2 for normal 
weight, overweight, and obese, respectively.
Adapting the BMI cutoff points proposed in Asian 
studies [13, 21], we analyzed a large cohort of Chinese 
patients with stage I NSCLC who underwent complete 
surgical resection to investigate the association between 
BMI and the survival of patients with stage I NSCLC, as 
well as complications after resection.
Patients and methods
Patient selection
This study was officially approved by the ethics com-
mittee of Sun Yat-sen University Cancer Center. We 
identified consecutive patients with stage I NSCLC 
(according to the 7th edition TNM classification) [22] 
who underwent complete surgical resection at Sun Yat-
sen University Cancer Center between December 2005 
and December 2010. Patients were excluded if they had 
received neoadjuvant chemotherapy, had an unknown 
BMI, had a history of other types of cancer, or had 
residual tumor tissue after surgery. Patient characteris-
tics and postoperative complications were analyzed. All 
of the patients underwent a lobectomy, bilobectomy, or 
pneumonectomy with complete lymph node dissection 
through the surgical approaches of open thoracotomy or 
video-assisted thoracoscopy.
BMI
BMI was calculated based on direct height and weight 
measurements before treatment. Specific BMI cutoff 
points for the Asian population have yet to be defined 
[18–20]. Therefore, we modified the BMI cutoff points 
proposed by Yang et  al. [13] (18.5, 20.0, 22.4, and 
25.0  kg/m2) and Koh et  al. [21] (20, 24, and 28  kg/m2) 
and divided the patients into four groups: underweight 
(BMI < 18.5 kg/m2), normal weight (BMI = 18.5–22.4 kg/
m2), overweight (BMI  =  22.5–28.0  kg/m2), and obese 
(BMI > 28.0 kg/m2).
Definitions of postoperative complications
All complications between the time of surgery and hos-
pital discharge were documented. Respiratory failure was 
defined as the requirement for postoperative mechanical 
ventilation longer than 24  h. Postoperative pyrexia was 
defined as a body temperature ≥38°C for a period >24 h 
following surgery. Chylothorax was defined as elevated 
triglyceride levels in milky drained fluid. Postoperative 
hemorrhage required reoperation. Myocardial infarc-
tion and arrhythmia were detected by electrocardiogram. 
Pneumothorax was detected by clinical observation and 
chest X-ray radiography. Atelectasis was detected by clin-
ical observation, chest X-ray radiography, and fiberoptic 
bronchoscopy. Perioperative death was defined as death 
within 1 month after surgery.
Follow‑up
Generally, the patients were followed every 3 months for 
the first year and twice a year thereafter. However, fol-
low-up interval was shortened for patients with specific 
symptoms. Regular follow-up examinations included a 
physical examination, blood chemistry analysis, tumor 
marker measurement, and computed tomography scan 
or chest X-ray radiography. The follow-up duration was 
calculated from the date of surgery to the date of the 
event or the last contact. Follow-up was continued until 
May 2015.
Statistical analysis
Statistical analyses were performed using SPSS 22.0 for 
Windows software (SPSS Inc., Chicago, IL, USA). Differ-
ences among the four BMI groups were tested using the 
Kruskal–Wallis test. The associations between BMI and 
clinicopathologic parameters or postoperative complica-
tions were analyzed using the Chi square test or Fisher’s 
exact test. Progression-free survival (PFS) was calculated 
from the date of surgery to the date of tumor recur-
rence, metastasis, or death from any cause. Overall sur-
vival (OS) was calculated from the date of surgery to the 
date of death from any cause. Survival curves were plot-
ted using the Kaplan–Meier method and analyzed using 
the log-rank test. A multivariate analysis was performed 
using the Cox proportional hazards regression model 
with the backward stepwise procedure (the entry and 
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removal probabilities were 0.05 and 0.10). A significant 




Seven hundred consecutive patients with stage I NSCLC 
underwent complete surgical resection between Decem-
ber 2005 and December 2010. Among them, 624 patients 
were included in the study and were divided into four 
groups according to BMI. The other 76 patients were 
excluded because they had received neoadjuvant chemo-
therapy (17 patients), had an unknown BMI (3 patients), 
had a history of other types of cancer (50 patients), had 
residual tumor tissue after surgery (4 patients), or a com-
bination of the above (2 patients).
The patient characteristics are shown in Table  1. As 
compared with a lower BMI, a higher BMI was associ-
ated with higher rates of hypertension (P < 0.001), smok-
ing (P = 0.001), and high preoperative forced expiratory 
volume in 1  s (FEV1)/forced vital capacity (FVC) ratios 
(P = 0.011). Normal weight patients were more likely to 
have visceral pleural invasion (P = 0.005) and to have a 
higher T stage (P  <  0.001) and TNM stage (P  <  0.001) 
than underweight, overweight, and obese patients.
Overweight and normal weight patients were less 
likely to experience postoperative respiratory fail-
ure (P  =  0.014) than underweight and obese patients, 
whereas obese patients were more likely to have myo-
cardial infarction after surgery (P =  0.033) than under-
weight, normal weight, and overweight patients. 
Furthermore, perioperative death was significantly less 
common in the overweight group than in other groups 
(P = 0.016, Table 2).
Univariate and multivariate analyses
The median follow-up duration of the entire cohort was 
63.2  months (range 47.8–78.1  months). The univari-
ate survival analysis showed significant differences in 
PFS and OS between the overweight group and other 
groups. The OS of overweight patients was significantly 
longer than those of underweight, normal weight, and 
obese patients (P  =  0.001; Table  3; Fig.  1). The PFS of 
overweight patients was significantly longer than those 
of patients in other groups (P =  0.034, Table  4; Fig.  2). 
The multivariate survival analysis showed that BMI was 
an independent factor associated with OS, and that over-
weight patients had a significantly lower risk of death 
from stage I NSCLC after surgery than did patients in 
other groups (compared with the underweight group: 
hazard ratio [HR]  =  2.24, 95% confidence interval 
[CI] 1.18–4.25, P  =  0.013; compared with the normal 
weight group: HR = 1.58, 95% CI 1.07–2.33, P = 0.022; 
compared with the obese group: HR  =  2.87, 95% CI 
1.48–5.59, P  =  0.002). Other independent factors that 
might affect OS included age, smoking history, extent of 
resection, histological differentiation, and T stage. Inde-
pendent factors that were associated with PFS included 
age, smoking, extent of resection, adjuvant chemother-
apy, BMI, and FEV1/FVC ratio.
Subgroup analysis
The univariate survival analyses showed that when 
stratified by smoking status and T stage, the association 
between being overweight and prolonged OS still existed 
(Table 5; Fig. 3).
Discussion
In our study, overweight patients showed a significantly 
longer OS than patients in other groups, as determined 
with both the univariate and multivariate survival anal-
yses. Overweight patients also had a longer PFS than 
patients in other groups, according to the univariate sur-
vival analysis. Furthermore, considering the potential 
effect of different T stages on the outcomes, we stratified 
the patients by T stage and re-tested the results. Using 
either the log-rank test or the Breslow test, we found that 
overweight patients had longer OS than did patients in 
other groups for each T stage, indicating the prognostic 
value of BMI in early-stage NSCLC.
The relationship between BMI and the risk of lung can-
cer has been studied widely in different patient popula-
tions [7, 8, 11–13, 21]. An inverse association between 
BMI and lung cancer mortality was reported in current 
smokers [13] and non-smokers [14, 15]. However, all of 
these studies focused primarily on epidemiology, includ-
ing all histological types or stages of lung cancer, but the 
treatment details were not provided. In the present study, 
we focused on operable stage I NSCLC and found that 
being overweight had a significant positive effect on the 
survival of stage I NSCLC patients after surgery. A low 
BMI (<18.5  kg/m2) has been shown to increase the risk 
of early postoperative death following en bloc chest wall 
and lung resection for NSCLC patients (P = 0.009) [23]. 
In addition, in a study of 640 patients after lobectomy for 
NSCLC, Tewari et al. [24] reported that a BMI < 18.5 kg/
m2 (as a surrogate for impaired nutrition) was a negative 
predictor of long-term survival independent of tumor 
extension and stage. In a large cohort study examining 
the effect of sex on the long-term outcomes of stage I 
NSCLC patients after curative resection, Warwick et  al. 
[25] also found that BMI was an independent prognostic 
factor (HR = 0.98, 95% CI 0.96–1.00, P = 0.02). Although 
patients were not grouped by BMI, these studies dem-
onstrated that a low BMI was a negative prognostic fac-
tor for NSCLC after resection. This finding may partly 
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Table 1 The baseline clinicopathologic characteristics of  underweight, normal weight, overweight, and  obese patients 
with stage I NSCLC, stratified by BMI











Total 624 44 245 306 29
Gender 0.668
 Male 408 (65.4) 26 (13.6) 166 (67.8) 198 (64.7) 18 (62.1)
 Female 216 (34.6) 18 (86.4) 79 (32.2) 108 (35.3) 11 (37.9)
Age (years) 0.991
 <60 285 (45.7) 20 (2.3) 114 (46.5) 138 (45.1) 13 (44.8)
 ≥60 339 (54.3) 24 (97.7) 131 (53.5) 168 (54.9) 16 (55.2)
Smoking 0.001
 Never 318 (51.0) 23 (4.5) 101 (41.2) 178 (58.2) 16 (55.2)
 Current or ever 306 (49.0) 21 (95.5) 144 (58.8) 128 (41.8) 13 (44.8)
Hypertension <0.001
 With 150 (24.0) 6 (13.6) 38 (15.5) 93 (30.4) 13 (44.8)
 Without 474 (76.0) 38 (86.4) 207 (84.5) 213 (69.6) 16 (55.2)
Diabetes 0.318
 With 46 (7.4) 1 (2.3) 18 (7.3) 23 (7.5) 4 (13.8)
 Without 578 (92.6) 43 (97.7) 227 (92.7) 283 (92.5) 25 (86.2)
Heart disease 0.482
 With 18 (2.9) 2 (4.5) 7 (2.9) 7 (2.3) 2 (6.9)
 Without 606 (97.1) 42 (95.5) 238 (97.1) 299 (97.7) 27 (93.1)
FEV1/FVC (%) 0.011
 <70 83 (13.3) 11 (25.0) 40 (16.3) 30 (9.8) 2 (6.9)
 ≥70 541 (86.7) 33 (75.0) 205 (83.7) 276 (90.2) 27 (93.1)
Type of surgery 0.979
 Open thoracotomy 537 (86.1) 37 (84.1) 210 (85.7) 264 (86.3) 25 (86.2)
 VATS 87 (13.9) 7 (15.9) 35 (14.3) 42(13.7) 4 (13.8)
Extent of resection 0.681
 Lobectomy or bilobec‑
tomy
611 (97.9) 44 (100.0) 239 (97.6) 299 (97.7) 29 (100.0)
 Pneumonectomy 13 (2.1) 0 (0.0) 6 (2.4) 7 (2.3) 0 (0.0)
Adjuvant chemotherapy 0.967
 Absent 486 (77.9) 34 (77.3) 193 (78.8) 236 (77.1) 23 (79.3)
 Present 138 (22.1) 10 (22.7) 52 (21.2) 70 (22.9) 6 (20.7)
Histological type 0.432
 Adenocarcinoma 406 (65.1) 29 (65.9) 152 (62.0) 203 (66.3) 22 (75.9)
 Squamous cell carci‑
noma
140 (22.4) 12 (27.3) 62 (25.3) 63 (20.6) 3 (10.3)




 Poor 212 (34.0) 17 (38.6) 94 (38.4) 92 (30.1) 9 (31.0)
 Moderate 300 (48.1) 17 (38.6) 113 (46.1) 159 (52.0) 11 (37.9)
 Well 112 (17.9) 10 (22.7) 38 (15.5) 55 (18.0) 9 (31.0)
Visceral pleural invasion 0.005
 Absent 408 (65.4) 32 (72.7) 140 (57.1) 212 (69.3) 23 (79.3)
 Present 216 (34.6) 12 (27.3) 105 (42.9) 94 (30.7) 6 (20.7)
T stage <0.001
 T1a 132 (21.2) 10 (22.7) 36 (14.7) 78 (25.5) 8 (27.6)
 T1b 113 (18.1) 13 (29.5) 31 (12.7) 59 (19.3) 9 (31.0)
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support our finding that survival was longer in over-
weight patients than in underweight and normal weight 
patients.
The mechanism by which being overweight might pro-
long patient survival is still not well understood. Some 
reports have explained that the association between BMI 
Underweight BMI < 18.5 kg/m2; normal weight BMI 18.5–22.4 kg/m2; overweight BMI = 22.5–28.0 kg/m2; obese BMI > 28.0 kg/m2
NSCLC non-small cell lung cancer, BMI body mass index, FEV1/FVC forced expiratory volume in 1 s/forced vital capacity, VATS video-assisted thoracic surgery
Table 1 continued











 T2a 379 (60.7) 21 (47.7) 178 (72.7) 169 (55.2) 12 (41.4)
Clinical TNM stage <0.001
 IA 245 (39.3) 23 (52.3) 67 (27.3) 137 (44.8) 17 (58.6)
 IB 379 (60.7) 21 (47.7) 178 (72.7) 169 (55.2) 12 (41.4)
Table 2 Postoperative complications of underweight, normal weight, overweight, and obese patients with stage I NSCLC











Total 624 44 245 306 29
Respiratory failure 0.014
 Absent 605 (97.0) 40 (90.9) 240 (98.0) 299 (97.7) 26 (89.7)
 Present 19 (3.0) 4 (9.1) 5 (2.0) 7 (2.3) 3 (10.3)
Pyrexia 0.965
 Absent 502 (80.4) 36 (81.8) 195 (79.6) 247 (80.7) 24 (82.8)
 Present 122 (19.6) 8 (18.2) 50 (20.4) 59 (19.3) 5 (17.2)
Chylothorax 0.339
 Absent 616 (98.7) 43 (97.7) 241 (98.4) 304 (99.3) 28 (96.6)
 Present 8 (1.3) 1 (2.3) 4 (1.6) 2 (0.7) 1 (3.4)
Hemorrhage 0.074
 Absent 612 (98.1) 44 (100.0) 236 (96.3) 303 (99.0) 29 (100.0)
 Present 12 (1.9) 0 (0.0) 9 (3.7) 3 (1.0) 0 (0.0)
Myocardial infarction 0.033
 Absent 618 (99.0) 44 (100.0) 243 (99.2) 304 (99.3) 27 (93.1)
 Present 6 (1.0) 0 (0.0) 2 (0.8) 2 (0.7) 2 (6.9)
Arrhythmia 0.484
 Absent 559 (89.6) 38 (86.4) 225 (91.8) 270 (88.2) 26 (89.7)
 Present 65 (10.4) 6 (13.6) 20 (8.2) 36 (11.8) 3 (10.3)
Pneumothorax 0.100
 Absent 473 (75.8) 29 (65.9) 179 (73.1) 240 (78.4) 25 (86.2)
 Present 151 (24.2) 15 (34.1) 66 (26.9) 66 (21.6) 4 (13.8)
Atelectasis 0.818
 Absent 579 (92.8) 40 (90.9) 228 (93.1) 283 (92.5) 28 (96.6)
 Present 45 (7.2) 4 (9.1) 17 (6.9) 23 (7.5) 1 (3.4)
Death 0.016
 Absent 614 (98.4) 42 (95.5) 240 (98.0) 305 (99.7) 27 (93.1)
 Present 10 (1.6) 2 (4.5) 5 (2.0) 1 (0.3) 2 (6.9)
Page 6 of 10Xie et al. Chin J Cancer  (2017) 36:7 
and lung cancer mortality is caused by smoking history 
[13]. A high smoking rate was found in patients with 
a low BMI, and smoking has been reported to have an 
negative effect on survival [26, 27]. In accordance with 
other studies [13, 16], we found that fewer overweight 
and obese patients were smokers as compared with 
underweight and normal weight patients. However, 
in the subgroup analysis, we found that the significant 
prognosis-protective effect of being overweight per-
sisted in non-smokers. In smokers, the overweight group 
had significantly longer survival than did other groups, 
as determined using the Breslow test, and while not sig-
nificant, this group also tended to show longer survival 
as measured using the log-rank test. Yang et al. [14] and 
Parr et al. [15] demonstrated that the inverse association 
between BMI and mortality persisted not only in smok-
ers but also in non-smokers. This finding indicates that 
BMI is an independent risk factor for lung cancer patient 
survival. After excluding patients who died within 
3 years after diagnosis, Leung et al. [16] also found that 
BMI was independently and negatively associated with 
death from lung cancer in smokers and never-smokers. 
This previous evidence and the findings of our study 
indicate that BMI is an independent factor for survival. 
The mechanism of the effect of BMI on the survival of 
NSCLC patients requires further investigation. Bren-
nan et al. [28] found that the fat mass- and obesity-asso-
ciated (FTO) gene, which is linked with increased BMI 
[29], was associated with a decreased risk of lung cancer. 
This finding provides us another perspective from which 
to consider how BMI affects the survival of lung cancer 
patients, although a direct association between lung can-
cer patient survival and the FTO gene has not yet been 
demonstrated.
Table 3 Univariate and multivariate overall survival (OS) analyses for patients with stage I NSCLC
The data of survival rates are expressed as mean ± standard error
HR hazard ratio, CI confidence interval
Variate OS rate (%) Univariate analysis
P value
Multivariate analysis
3‑year 5‑year HR (95% CI) P value
Age (years) 0.002 1.83 (1.26–2.64) 0.001
 <60 92.6 ± 1.6 85.6 ± 2.2
 ≥60 85.8 ± 1.9 77.1 ± 2.4
Smoking <0.001 1.45 (1.05–2.10) 0.047
 Never 94.1 ± 1.3 86.4 ± 2.0
 Current or ever 83.4 ± 2.2 75.1 ± 2.6
BMI 0.001 0.003
 Underweight 84.0 ± 5.5 75.8 ± 6.7 0.012 2.24 (1.18–4.25) 0.013
 Normal weight 84.2 ± 2.4 75.5 ± 2.9 <0.001 1.58 (1.07–2.33) 0.022
 Overweight 94.8 ± 1.3 87.7 ± 2.0 Reference Reference Reference
 Obese 75.9 ± 7.9 65.3 ± 8.9 0.002 2.87 (1.48–5.59) 0.002
Extent of resection <0.001 5.01 (2.26–11.07) <0.001
 Lobectomy or bilobectomy 89.6 ± 1.3 81.6 ± 1.6
 Pneumonectomy 51.3 ± 15.8 41.0 ± 15.6
Histological differentiation 0.001 0.76 (0.58–0.99) 0.039
 Poor 83.0 ± 2.7 73.5 ± 3.2
 Moderate 91.5 ± 1.6 84.0 ± 2.2
 Well 93.2 ± 2.5 86.7 ± 3.5
T stage 0.005 1.40 (1.08–1.80) 0.011
 T1a 93.8 ± 2.1 90.4 ± 2.7
 T1b 89.0 ± 3.0 82.0 ± 3.8
 T2a 87.3 ± 1.8 77.3 ± 2.3
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In the current study, although being overweight 
appeared to prolong survival in stage I NSCLC patients, 
the obese group had a similar outcome as the normal 
and underweight groups. This finding contradicts those 
of other studies [13, 14], in which the obese group of 
lung cancer patients usually had the lowest mortality. 
However, these studies were based on all types of pul-
monary malignancies, including small cell lung cancer 
and advanced-stage NSCLC, which have a poor progno-
sis. Stage I NSCLC in particular is biased toward non-
cancer-related death because patients are more likely to 
be cured and to have a long life expectancy. The obese 
patients in our study actually had higher rates of preop-
erative diseases, such as hypertension, as well as post-
operative complications, such as respiratory failure and 
myocardial infarction, compared with patients in other 
groups. These complications might cause poor health 
after surgery and may lead to death early after treatment. 
Using data from the Asia-Pacific Cohort Studies Collabo-
ration, Parr et al. [14] examined the association between 
BMI and mortality from over 20 cancer sites in adults 
and found a result similar to ours. They compared nor-
mal weight and obese groups and found that significantly 
lower lung cancer mortality persisted in the overweight 
Fig. 1 Kaplan–Meier overall survival (OS) curves of patients with stage I non‑small cell lung cancer (NSCLC) stratified by body mass index (BMI). 
Underweight BMI < 18.5 kg/m2; normal weight BMI 18.5–22.4 kg/m2; overweight BMI 22.5–28.0 kg/m2; and obese: BMI > 28.0 kg/m2. a The OS was 
longer in the overweight group than in other groups in combination (P = 0.001). b The OS was longer in the overweight group than in the under‑
weight group (P = 0.012), the normal weight group (P = 0.001), and the obese group (P = 0.002)
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Table 4 Univariate and multivariate progression-free survival (PFS) analyses for patients with stage I NSCLC
The data of survival rates are expressed as mean ± standard error. Abbreviations as in Tables 1 and 3
Variate PFS rate (%) Univariate analysis
P value
Multivariate analysis
3‑year 5‑year HR (95% CI) P value
Age (years) 0.068 1.45 (1.09–1.93) 0.011
 <60 79.4 ± 2.4 69.9 ± 2.8
 ≥60 73.9 ± 2.4 65.0 ± 2.7
Smoking 0.003 1.43 (1.08–1.90) 0.014
 Never 80.8 ± 2.2 72.2 ± 2.6
 Current or ever 71.9 ± 2.6 62.0 ± 2.9
BMI 0.034 1.28 (0.97–1.68) 0.080
 Overweight 80.2 ± 2.3 71.1 ± 2.7
 Others 72.9 ± 2.5 63.6 ± 2.8
Extent of resection <0.001 4.71 (2.23–9.97) <0.001
 Lobectomy or bilobectomy 77.2 ± 1.7 68.0 ± 2.0
 Pneumonectomy 38.4 ± 14.7 28.8 ± 13.8
FEV1/FVC (%) 0.910 0.70 (0.46–1.07) 0.096
 <70 76.3 ± 1.9 67.3 ± 2.1
 ≥70 77.6 ± 4.7 66.8 ± 5.4
Adjuvant chemotherapy 0.128 1.39 (1.01–1.91) 0.043
 Absent 77.6 ± 1.9 68.7 ± 2.2
 Present 72.3 ± 3.9 61.8 ± 4.4
Fig. 2 Kaplan–Meier progression‑free survival (PFS) curves of patients with stage I NSCLC stratified by BMI. a The PFS was longer in the overweight 
group than in other groups in combination (P = 0.034). b The PFS was longer in the overweight group than in the normal weight group (P = 0.045), 
but differences were not significant between the overweight group and the underweight group (P = 0.172) and the obese group (P = 0.514)
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group in both smokers and non-smokers. Therefore, 
there was a U-shaped relation between BMI and lung 
cancer mortality. There have been few studies on the 
association between BMI and operable stage I NSCLC. 
The number of obese patients in our study was limited. 
Therefore, our results must be interpreted with caution.
We acknowledge some limitations in our study. 
Because BMI cutoff points have yet to be defined for the 
Asian population, patient grouping may lead to a selec-
tion bias. Additionally, we failed to explain the mecha-
nism of how BMI affects lung cancer patient survival. 
Biomarkers and genetic markers should be used in fur-
ther research on this topic.
Conclusions
Being overweight appears to be more favorable than 
being obese, normal weight, and underweight for the 
survival of patients with stage I NSCLC after complete 
surgical resection. Among either non-smokers or smok-
ers, overweight patients had significantly longer survival 
than underweight, normal weight, and obese patients. 
The mechanism of how BMI affects lung cancer patient 
survival remains to be elucidated.
Table 5 Subgroup OS analysis for  stage I NSCLC patients 
in  the overweight group and  other groups, stratified 
by smoking status and T stage
The data of survival rates are expressed as mean ± standard error
Prognostic 
factor
OS rate (%) Univariate analysis





 Overweight 98.2 ± 1.0 92.1 ± 2.2
 Others 89.1 ± 2.7 79.4 ± 3.6
Smoking 0.083 0.024
 Overweight 89.9 ± 2.8 81.2 ± 3.7
 Others 78.8 ± 3.1 70.7 ± 3.5
T1a stage 0.024 0.004
 Overweight 100.0 ± 0 97.0 ± 2.1
 Others 85.0 ± 4.9 81.1 ± 5.4
T1b stage 0.051 0.040
 Overweight 94.8 ± 2.9 87.0 ± 4.6
 Others 82.4 ± 5.3 76.3 ± 6.0
T2a stage 0.020 0.005
 Overweight 92.4 ± 2.1 83.5 ± 3.1
 Others 83.2 ± 2.6 72.5 ± 3.2
Fig. 3 Kaplan–Meier OS curves of stage I NSCLC patients in the overweight group and other groups in combination stratified by smoking status 
and T stage. a The OS was longer in the overweight group than in other groups in combination (P = 0.001); b in non‑smoking patients, the OS 
was longer in the overweight group than in other groups in combination (P = 0.001); c in smoking patients, the difference in OS was insignificant 
between the overweight group and other groups in combination (P = 0.083); d in patients with T1a stage NSCLC, the OS was longer in the over‑
weight group than in other groups in combination (P = 0.024); e in patients with T1b stage NSCLC, the difference in OS was insignificant between 
the overweight group and other groups in combination (P = 0.051); and f in patients with T2a stage NSCLC, the OS of the overweight group was 
longer than that of other groups in combination (P = 0.020)
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